

### Polycystic ovary syndrome: assessment and management Guideline Committee Meeting 5



**Date:** 11/112025

**Location:** Hybrid (Manchester)

**Minutes:** Final

Committee members present:	
Rebecca Payne (Chair)	Present for agenda items 1-8 (in-person)
Clare Devanney-Glynn	Present for agenda items 1-2 (in-person), 3 to 8 (virtual)
Catherine Gallagher (Co-opted Committee member)	Present for agenda items 1-8 (in-person)
Araya Gautam	Present for agenda items 1-3 (partway) (in-person)
Hassan Kahal (Co-opted Committee member)	Present for agenda items 1-8 (in-person)
Punith Kempegowda	Present for agenda items 1-8 (in-person)
Judith Ibison	Present for agenda items 1-8 (in-person)
Sharon Manship	Virtual
Raj Mathur	Present for agenda items 1-8 (in-person)
Samantha Montes	Present for agenda items 1-8 (virtual)
Chetna Patel	Present for agenda items 1-8 (in-person)
Aled Rees	Present for agenda items 1-8 (in-person)
Nadia Rahman	Present for agenda items 1-8 (virtual)
Bassel Wattar	Present for agenda items 1-2 (in-person)

In attendance:		
Alexandra Bonnon	Health Economist	Present for agenda items 1-8 (in-person)
Bethan Dorsett	Senior Guidance Content Designer	Present for agenda items 1-8 (in-person)
Sophia Kemmis-Betty	Health Economics Adviser	Present for agenda items 1-8 (partway) (virtual)

#### 4.0.03 DOC Cmte minutes

Clifford Middleton	Topic Lead	Present for agenda items 1-8 (in-person)
Vonda Murray	Project Manager	Present for agenda items 1-8 (in-person)
Suzie Panek	Resource Impact Lead	Present for agenda items 1-8 (virtual)
Julie Neilson	Senior Technical Analyst	Present for agenda items 1-8 (virtual)
Charlotte Rawstrone	Technical Analyst	Present for agenda items 1-6 (partway) (virtual)

#### Apologies:

Martin Allaby	NICE- Consultant Clinical Advisor
Guy Morris	Committee member
Cheryl Pace	NICE - Medicines Adviser

#### 1. Welcome, aim of meeting, housekeeping, introductions and apologies

The Chair welcomed the Committee members and attendees to the guideline committee meeting 5 on Polycystic ovary syndrome: assessment and management Guideline. The Chair informed the committee that apologies had been received, these are noted above. The Chair noted no declarations of interest were made.

#### 2. Section 4.8 Hair reduction

The Chair introduced Julie Neilson, Senior Technical Analyst who gave a presentation on laser hair reduction. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Julie Neilson for her presentation and contribution to the development of the guideline.

#### 3. Other section 1 reviews: technical checks

- **1.8 Cardiovascular disease**
- **1.9 Impaired glucose tolerance and type 2 diabetes**
- **1.10 Sleep apnea Part 1**
- **1.11 Endometrial cancer**
- **1.12 Risk in relatives**

The Chair introduced Julie Neilson, Senior Technical Analyst who gave a presentation on the technical checks for sections 1.8 to 1.12 of the international guideline. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Julie Neilson for her presentation and contribution to the development of the guideline.

#### 4. Other section 1 reviews: economic considerations

- **1.8 Cardiovascular disease**
- **1.9 Impaired glucose tolerance and type 2 diabetes**
- **1.10 Sleep apnea Part 1**

#### 4.0.03 DOC Cmte minutes

<ul style="list-style-type: none"><li>• <b>1.11 Endometrial cancer</b></li><li>• <b>1.12 Risk in relatives</b></li></ul>
<p>The Chair introduced Alexandra Bonnon, Health Economist who went through the economic consideration for sections 1.8 to 1.12 of the international guideline. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Alexandra Bonnon for her presentation and contribution to the development of the guideline.</p>
<p><b>5. Other section 1 reviews: recommendations</b></p> <ul style="list-style-type: none"><li>• <b>1.8 Cardiovascular disease</b></li><li>• <b>1.9 Impaired glucose tolerance and type 2 diabetes</b></li><li>• <b>1.10 Sleep apnea Part 1</b></li><li>• <b>1.11 Endometrial cancer</b></li><li>• <b>1.12 Risk in relatives</b></li></ul>
<p>The Chair introduced Clifford Middleton, Topic Lead who went through the recommendations for diagnosis (non-PCOM reviews). The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Clifford Middleton.</p>
<p><b>6. Biochemical hyperandrogenism recommendations</b></p>
<p>The Chair introduced Clifford Middleton, Topic Lead who went through the recommendations for Biochemical hyperandrogenism. The Committee then discussed the issues presented in relation to this guideline. The Chair thanked Clifford Middleton.</p>
<p><b>7. Actions and decisions</b></p> <p><b>Any other business</b></p>
<p>The chair reminded everyone that committee members should let the Project Manager know no later than one week before if they are not attending the full committee meetings.</p>
<p><b>8. Close of meeting</b></p>
<p>The Chair closed the meeting.</p>

**Date of next meeting:** 13/01/2026 and 14/01/2026

**Location of next meeting:** Zoom